MD Newsline

Welcome to The MD Newsline Podcast, where we bring you the latest insights at the intersection of healthcare and innovation. Join us as we dive deep into the medical breakthroughs, clinical trial updates, and industry best practices shaping the future of patient care. Each episode features thought-provoking conversations with leading healthcare professionals, researchers, and advocates tackling the biggest challenges in medicine today. We uncover the strategies and innovations that are transforming the way care is delivered. If you're a healthcare provider, industry leader, or simply passionate about advancing medical education, this is your go-to resource for expert knowledge and actionable insights. Tune in, stay informed, and be part of the movement toward a healthier future.

AI, HER2-Low, and the Future of Precision Oncology 05/05/2026

AI, HER2-Low, and the Future of Precision Oncology In this episode of MD Newsline, Dr Frederick Howard, breast oncologist at the University of Chicago and leader of a research group focused on AI-driven biomarker development, explores the rapidly evolving role of artificial intelligence in breast cancer care. Dr. Howard provides a comprehensive overview of how AI is being integrated into oncology—from radiographic imaging and digital pathology to clinical decision support and language models. He discusses both the promise and the practical challenges of deploying AI tools in real-world workflows, including validation standards, regulatory guardrails, and ethical considerations. The conversation also dives into emerging applications such as AI-based HER2 quantification, recurrence risk prediction from H&E slides, and the potential for multimodal models to transform precision medicine. Episode Highlights: AI in Radiology and Mammography Dr. Howard explains the evolution from early computer-aided detection systems to modern deep learning algorithms trained on millions of mammograms. He discusses emerging AI-driven breast cancer risk prediction tools derived directly from imaging and how they may enhance early detection strategies. Digital Pathology and Biomarker Development AI tools are increasingly capable of quantifying immunohistochemistry and identifying features beyond human visual interpretation. Dr. Howard highlights research presented at major oncology meetings demonstrating improved concordance in HER2-low classification and improved reproducibility in biomarker scoring. Predicting Recurrence Risk Without Genomic Testing One of the most promising areas involves AI models trained on H&E slides to predict recurrence risk—potentially matching or exceeding established genomic assays such as Oncotype DX and MammaPrint. Dr. Howard discusses the validation challenges required before these tools can replace or complement genomic testing in clinical practice. HER2-Low Classification and Antibody-Drug Conjugates The discussion explores limitations of traditional HER2 immunohistochemistry, especially at the lower end of expression. AI-based quantitative approaches may improve patient stratification for HER2-directed antibody-drug conjugates, though questions remain about predictive thresholds and biological mechanisms. Language Models in Oncology Practice Dr. Howard examines the growing use of large language models for literature review, documentation support, and clinical trial matching. He emphasizes the need for HIPAA-compliant systems, clinician oversight, and standardized evaluation frameworks to ensure safe and responsible deployment. Ethics, Governance, and Over-Reliance From data privacy to clinical accountability, the episode addresses the ethical considerations surrounding AI in cancer care. Dr. Howard cautions against over-reliance on AI systems and underscores the importance of maintaining clinician expertise and critical thinking. The Future: Multimodal AI and Precision Medicine Looking ahead, Dr. Howard envisions a future where digital pathology, genomics, imaging, and clinical data converge into multimodal AI systems capable of delivering truly personalized treatment recommendations. He stresses that large-scale data sharing and collaboration will be essential to realizing this potential. Key Takeaway Artificial intelligence is no longer theoretical in oncology—it is actively shaping diagnostics, risk stratification, and treatment selection in breast cancer. However, rigorous validation, ethical governance, and thoughtful integration into clinical workflows are critical to ensuring that AI enhances—rather than replaces—expert clinical judgment. Resources: Website: Newsletter: Contact with Dr. Frederick Howard: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40223840

Late-Stage Breast Cancer Diagnosis Among Black Women in the Mid-South 04/28/2026

Late-Stage Breast Cancer Diagnosis Among Black Women in the Mid-South In this episode of MD Newsline, Dr. Janeane N. Anderson, Assistant Professor at the University of Tennessee Health Science Center and breast cancer researcher, shares insights from the ACCESS Study—an innovative qualitative research initiative focused on understanding why Black women in the Mid-South region are disproportionately diagnosed with advanced-stage breast cancer. Dr. Anderson discusses structural barriers, community-based recruitment strategies, and the importance of centering lived experiences in oncology research. She also highlights the critical need for equitable research participation, race- and gender-concordant research teams, and stronger clinician engagement to improve outcomes for underserved populations. Episode Highlights: Understanding Advanced-Stage Breast Cancer in the Mid-South Dr. Anderson explains how the Mississippi Delta region represents a “cancer hotspot,” with higher rates of late-stage diagnoses and mortality among Black women. She explores how structural vulnerability, transportation challenges, cultural norms, and fragmented healthcare systems contribute to disparities. The ACCESS Study: A Community-Centered Research Design The ACCESS Study is a three-year qualitative investigation examining socio-ecological factors that increase the likelihood of de novo metastatic breast cancer diagnoses among Black women. Dr. Anderson outlines her multi-method approach, including: · In-depth interviews with photo elicitation · Ethnographic “go-alongs” in participants’ neighborhoods · Observations during clinic visits · Interviews with regional clinicians This immersive methodology allows researchers to understand not just clinical outcomes, but the lived realities shaping patient journeys. Barriers to Recruitment and Participation Recruiting women with metastatic breast cancer presents unique challenges. Dr. Anderson discusses barriers such as: · Health status and treatment burden · Caregiving responsibilities · Transportation and rural geography · Income instability and housing challenges · Research mistrust rooted in sociohistorical and contemporary inequities She emphasizes that participation barriers are often structural—not a lack of interest. Recruitment Strategies That Worked Dr. Anderson highlights the importance of race- and gender-concordant research teams, which foster trust and cultural understanding. Additional effective strategies included: · Leveraging electronic health records for efficient identification · Community-based outreach in churches, libraries, salons, and local organizations · Multiple consent touchpoints to address concerns and build rapport Her key message to clinicians: Ask. Many eligible patients are interested in research—but are never invited. Moving Beyond Accrual Metrics Dr. Anderson argues that equitable research should not be measured by numbers alone. Individual stories—“n of 1” experiences—reveal intersectional traumas and systemic barriers that large datasets may overlook. She advocates for qualitative methodologies to better understand the “why” behind disparities. Sexual Health and Survivorship At the San Antonio Breast Cancer Symposium, Dr. Anderson also noted the need for greater focus on oncosexology. Sexual health remains one of the most unmet needs in breast cancer survivorship, impacting quality of life, adherence, and overall well-being. Key Takeaway Dr. Anderson underscores that addressing disparities in advanced breast cancer requires more than clinical innovation. It demands community engagement, culturally concordant research teams, clinician advocacy, and methodologies that center the lived experiences of Black women. True equity begins with listening—and asking. Resource Website: Newsletter: Contact with Dr. Janeane N. Anderson: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40211635

Understanding Cancer Disparities, Mistrust, and Access to Care 04/21/2026

Understanding Cancer Disparities, Mistrust, and Access to Care In this episode of MD Newsline, Dr. Jordonna Brown, a medical oncologist at Kings County Hospital in New York City, shares her frontline experience caring for patients in a safety-net hospital setting. Speaking from the San Antonio Breast Cancer Symposium (SABCS), Dr. Brown discusses cancer disparities, late-stage presentation, mistrust in the healthcare system, and the evolving landscape of breast cancer treatment. She offers a candid look at the social determinants of health shaping patient outcomes—from delayed screening and misconceptions about chemotherapy to barriers in long-term adherence and clinical trial participation. Episode Highlights: Late-Stage Presentation and Screening Gaps Dr. Brown highlights a concerning trend: many patients present with advanced-stage breast cancer due to missed routine mammograms. Barriers include misconceptions about radiation exposure, fear of pain, religious beliefs, and lack of awareness about updated screening guidelines starting at age 40. Mistrust and Chemotherapy Misconceptions One of the most persistent challenges is distrust in the medical system. Patients often fear that chemotherapy may be more harmful than beneficial. Dr. Brown emphasizes the importance of patient-centered communication, empathy, and transparent education to build trust and empower informed decisions. Younger Patients and Aggressive Disease Breast and colon cancers are increasingly diagnosed in younger populations. In women under 40, breast cancer often demonstrates more aggressive tumor biology. Younger patients also face unique psychosocial challenges, including body image concerns, fertility considerations, career disruptions, and adherence to long-term maintenance therapy. Socioeconomic Barriers and Access to Care Financial instability, employment loss, transportation issues, and food insecurity can significantly impact adherence and long-term outcomes. Dr. Brown discusses how institutional support—such as social services, transportation programs, counseling, and food banks—helps mitigate these barriers. Clinical Trials and Underrepresentation Dr. Brown notes persistent skepticism around clinical trials among underrepresented communities. She underscores the need for improved education, emphasizing that today’s standard treatments are the result of prior clinical trials—and that participation advances care for future generations. Emerging Therapies and Personalized Medicine At SABCS, Dr. Brown was encouraged by advances in early-stage hormone-positive breast cancer, including new selective estrogen receptor degraders (SERDs) such as giredestrant, which may offer improved tolerability compared to traditional endocrine therapies. She also discusses the growing role of artificial intelligence in shaping cancer care and the importance of ensuring diverse data representation in AI-driven tools. Mental Health and Survivorship The emotional and social impact of a cancer diagnosis often extends beyond treatment. Family dynamics, job security, and mental health are frequently under-addressed areas. Dr. Brown advocates for integrated palliative care, psychotherapy services, and survivorship groups to support patients holistically. Key Takeaway Addressing breast cancer disparities requires more than medical innovation—it demands trust-building, education, equitable access, and culturally sensitive communication. By partnering with patients, improving representation in clinical research, and strengthening community-based support systems, clinicians can meaningfully improve outcomes across diverse populations. Resources: Website: Newsletter: Contact with Dr. Jordonna Brown: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40211610

Inflammation and Resistance in MDS & AML: Targeting the JAK-STAT Axis 04/14/2026

Inflammation and Resistance in MDS & AML: Targeting the JAK-STAT Axis In this episode of MD Newsline, Dr. Theodoros Karantanos, Assistant Professor of Medical Oncology at the Johns Hopkins University Sidney Kimmel Cancer Center, discusses the emerging role of inflammatory signaling in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Dr. Karantanos shares insights from his laboratory research exploring how inflammatory pathways—particularly interferon gamma and JAK-STAT signaling—contribute to treatment resistance, including resistance to venetoclax. He also highlights the impact of TP53 mutations, bone marrow microenvironment dynamics, and post-translational modifications in shaping disease progression and therapeutic response. Episode Highlights: Inflammatory Signaling and Venetoclax Resistance High-risk MDS and AML frequently demonstrate upregulation of inflammatory pathways. Dr. Karantanos explains how interferon gamma signaling activates the JAK-STAT cascade (JAK1/2, STAT1/3/5), leading to transcriptional programs associated with resistance to venetoclax and chemotherapy. The Role of TP53 in Driving Inflammation Loss of TP53 function not only impairs apoptosis but may intrinsically upregulate interferon gamma signaling within leukemic cells. This cell-intrinsic inflammatory activation may partially explain why TP53-mutated MDS and AML remain particularly difficult to treat. Post-Translational Modifications as Resistance Drivers Phosphorylation and ubiquitination play central roles in regulating inflammatory cascades. Dr. Karantanos emphasizes that proteomic and phospho-signature analyses are essential, as RNA expression alone cannot fully capture pathway activation under therapeutic pressure. Bone Marrow Microenvironment and Cytokine Crosstalk The bone marrow niche—including fibroblasts, adipocytes, endothelial cells, and immune subsets—contributes to resistance through cytokine secretion (e.g., IL-1β, TNF-α) and drug metabolism. These interactions reshape therapeutic exposure and promote survival of malignant clones. Monocytic Leukemias and Inflammatory Activation Monocytic AML subtypes (M4/M5) appear particularly enriched in inflammatory signaling, including interferon gamma and TNF-α activation. These subsets may represent high-priority targets for inflammation-modulating strategies. Targeting Inflammatory Pathways: Translational Strategies Potential therapeutic approaches include IRAK1/IRAK4 inhibitors, JAK pathway modulation, and antibody-drug conjugates targeting downstream interferon-regulated surface proteins such as CCRL2 and ICAM-1. Combination and triplet regimens may offer future improvements over venetoclax-based standards. Single-Cell and Spatial Transcriptomics Dr. Karantanos highlights the importance of computational biology, single-cell RNA sequencing, and spatial transcriptomics in deciphering the complex inflammatory networks within the bone marrow microenvironment. These technologies are critical for identifying actionable nodes and refining patient stratification. Key Takeaway Inflammatory signaling is not merely a bystander in myeloid neoplasms—it is a central driver of disease evolution and therapeutic resistance. Integrating inflammatory biomarkers, post-translational pathway profiling, and microenvironmental analysis may unlock new precision strategies for high-risk MDS and AML, particularly in TP53-mutated and monocytic subtypes where unmet need remains greatest. Resources: Website: Newsletter: Contact With Dr. Theodoros Karantanos: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40211580

Host Factors in Immunotherapy: How Sex, Aging, and Lifestyle Shape Cancer Outcomes 04/07/2026

Host Factors in Immunotherapy: How Sex, Aging, and Lifestyle Shape Cancer Outcomes In this episode of MD Newsline, Dr. Marco Ruella, Associate Professor of Medicine at the University of Pennsylvania and Scientific Director of the Lymphoma Program, joins us from the American Society of Hematology (ASH) meeting to discuss a paradigm-shifting topic: host factors in cancer immunotherapy. Dr. Ruella explores how biological sex, aging, chronic inflammation, obesity, exercise, and the microbiome influence responses to therapies such as checkpoint inhibitors and CAR T-cell therapy. The conversation highlights emerging data, translational research, and the growing need to capture holistic patient information to optimize outcomes. Episode Highlights: Why Host Factors Matter in Immunotherapy Traditional clinical trials focus heavily on tumor biology, but host characteristics—including sex, age, metabolic state, and lifestyle—also shape immune responsiveness. Dr. Ruella explains how incorporating these variables can help explain why only a subset of patients achieve durable benefit. Sex-Based Differences in Immune Response Research suggests meaningful biological differences in cancer incidence, immune activation, and treatment outcomes between males and females. Female patients often demonstrate a more “inflamed” or “hot” tumor microenvironment, potentially contributing to stronger immune responses. Hormonal influences, X-linked immune genes, and lifestyle factors may all contribute. Chronic vs. Acute Inflammation Inflammation is a double-edged sword. While acute inflammation after therapy can enhance anti-tumor effects, chronic baseline inflammation is associated with poorer outcomes and greater toxicity in CAR T-cell therapy. Biomarkers such as ferritin, IL-6, CRP, and ESR may help stratify risk. Aging and Biological Fitness Chronological age alone does not predict immunotherapy outcomes. Instead, biological fitness and muscle mass (sarcopenia) may be more relevant predictors of response and toxicity. Emerging research aims to better define “biological age” to guide treatment decisions. Microbiome, Diet, and Metabolism Dr. Ruella shares compelling data linking gut microbiome diversity to CAR T-cell efficacy. Antibiotic exposure before therapy has been associated with poorer outcomes. Additionally, ketogenic diets and ketone bodies such as beta-hydroxybutyrate are being explored to enhance T-cell function in clinical trials. Exercise as an Immune Modulator Short-term exercise can mobilize NK cells and T cells into circulation, potentially priming the immune system before immunotherapy. Ongoing trials are investigating whether structured exercise programs may improve treatment efficacy. AI, Wearables, and the Future of Data Capture To fully understand host factors, clinicians must systematically collect data on diet, exercise, sleep, and inflammation. Wearables, mobile applications, and artificial intelligence may enable more comprehensive, multi-omic profiling and personalized immunotherapy strategies. Key Takeaway Cancer immunotherapy is not determined solely by tumor biology—it is profoundly shaped by the host. Sex differences, chronic inflammation, metabolic health, and lifestyle factors all influence immune function and treatment response. Integrating these variables into clinical research and real-world practice may unlock more precise, equitable, and effective immunotherapy strategies. Resources: Website: Newsletter: Contact with Dr Marco Ruella: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40160695

What’s Next for CAR-T Cells? In Vivo Design, Toxicity, and Persistence 03/31/2026

What’s Next for CAR-T Cells? In Vivo Design, Toxicity, and Persistence In this episode of MD Newsline, Dr. Dejah Blake, a fifth-year PhD candidate at Emory University, joins us from the American Society of Hematology (ASH) conference to discuss the rapidly evolving landscape of CAR T-cell therapy. Dejah shares insights into engineering next-generation CAR T cells, improving accessibility through in vivo manufacturing, and addressing diversity gaps in clinical research. From armored CARs to gene editing and humanized mouse models, this conversation explores how innovation and equity must move forward together in advancing cancer immunotherapy. Episode Highlights: In Vivo CAR T Cells and Accessibility Traditional CAR T-cell therapy is often described as a “boutique” treatment—highly personalized and complex to manufacture. Dejah explains how in vivo CAR T strategies, including viral vectors and gene-editing approaches, could offer more accessible, potentially off-the-shelf options. Reducing manufacturing time and cost may significantly expand patient access. Gene Editing and the Next Frontier Gene editing technologies are reshaping how scientists design immune cells. Dejah discusses how advances in vector engineering, nanoparticles, and genome modification are transforming the field—not just for cancer, but for broader therapeutic applications. Armored CAR T Cells and Micro-Pharmacies Armored CAR T cells—engineered to secrete cytokines or other immune-modulating factors—represent an exciting innovation. These enhanced cells may help overcome tumor heterogeneity, antigen escape, and hostile tumor microenvironments, particularly in solid tumors. Persistence and the Tumor Microenvironment One of the biggest challenges in CAR T-cell therapy is ensuring persistence in immunosuppressive tumor environments. The discussion explores strategies to generate stem cell–like CAR T cells, balance memory and effector functions, and resist chronic antigen stimulation. Preclinical Models and Translational Science Dejah explains the importance—and limitations—of mouse models, including humanized and patient-derived xenograft (PDX) systems. While essential for mechanistic insight, these models do not always predict first-in-human outcomes, underscoring the need for thoughtful translational design. Retrospective Data, AI, and Clinical Blind Spots As more patients receive CAR T therapy, retrospective analyses are revealing patterns in durability, toxicity, and response. The conversation also addresses data blind spots—particularly regarding racial, socioeconomic, and age diversity—and emphasizes the importance of equitable representation in clinical research. Bridging Bench to Bedside Dejah highlights the growing collaboration between academia and industry in advancing cell therapy. Funding models, clinician-researcher partnerships, and patient-centered translational thinking are essential to moving discoveries from laboratory to clinic responsibly. Key Takeaway The future of CAR T-cell therapy depends not only on technological innovation—such as gene editing and in vivo engineering—but also on accessibility, diversity, and translational collaboration. By combining scientific rigor with equity-focused research, the next generation of immunotherapy can become more effective, scalable, and inclusive. Resources: Website: Newsletter: Contact with Dr. Dejah Blake: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40160645

The Psychology of Prevention: Behavioral Strategies for Better Health Outcomes 03/24/2026

The Psychology of Prevention: Behavioral Strategies for Better Health Outcomes In this episode of MD Newsline, behavioral scientist Dr. Josh Klapow, registered dietitian Kim Shapira, and health advocate Sishman Rimpson explore the powerful connection between psychology, nutrition, and long-term health outcomes. Together, they unpack how behavioral patterns, mindset, and sustainable lifestyle changes influence chronic disease prevention and patient adherence. The discussion highlights the real-world challenges patients face when attempting to modify diet, physical activity, and stress management—and how healthcare professionals can better support lasting change through practical, evidence-based strategies. Episode Highlights: The Role of Behavioral Psychology in Healthcare Dr. Klapow explains how behavioral science plays a foundational role in chronic disease prevention and management. He discusses why knowledge alone does not change behavior and how emotional drivers, habit formation, and environmental cues shape patient decisions. Nutrition as a Sustainable Lifestyle, Not a Short-Term Fix Kim Shapira emphasizes the importance of shifting from restrictive dieting to sustainable eating patterns. She outlines practical approaches to portion awareness, mindful eating, and building a healthy relationship with food—strategies that promote long-term success rather than temporary results. Patient Adherence and Motivation The panel discusses common barriers to adherence, including stress, misinformation, unrealistic expectations, and social pressures. They explore how clinicians can foster accountability while maintaining empathy and realistic goal-setting. Bridging Mental and Physical Health Sishman Rimpson highlights the importance of integrating mental health awareness into routine medical care. Addressing stress, sleep, and emotional well-being can significantly enhance patient engagement and treatment outcomes. Preventive Care and Community Impact The conversation also explores how preventive strategies—when implemented at both individual and community levels—can reduce the burden of chronic diseases such as obesity, diabetes, and cardiovascular disease. Key Takeaway Sustainable health outcomes require more than prescriptions—they demand behavioral insight, patient-centered communication, and collaborative care. By integrating psychology, nutrition science, and practical lifestyle strategies, healthcare professionals can empower patients to make meaningful, lasting changes. Resources: Website: Newsletter: Contact with panelist: · Josh Klapow: · Kim Shapira: · Sishman Rimpson: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40160625

Beyond Statins: Modern Cholesterol Care, Risk Assessment, and the Future of Lipid Therapy 03/17/2026

Beyond Statins: Modern Cholesterol Care, Risk Assessment, and the Future of Lipid Therapy In this episode of MD Newsline, Dr. Amber Johnson, Assistant Professor of Medicine and General Cardiologist at the University of Chicago, provides an in-depth look at modern cholesterol management and cardiovascular risk reduction. She discusses evolving lipid guidelines, aggressive LDL-C targets, statin intolerance, and the growing role of non-statin therapies. Dr. Johnson also explores emerging research on lipoprotein(a), hypertriglyceridemia, and future directions in lipid-lowering treatment. Episode Highlights Evolving Cholesterol Management and ASCVD Risk Dr. Johnson explains how cholesterol treatment has become more aggressive over the past decade, driven by robust evidence linking LDL cholesterol to cardiovascular events. She emphasizes LDL-C as the primary treatment target and discusses the role of HDL, triglycerides, and inflammatory markers such as high-sensitivity CRP, particularly in women. Lifestyle Modification and Population-Level Prevention Heart-healthy lifestyle interventions remain foundational to cardiovascular prevention. Dr. Johnson highlights the American Heart Association’s Life’s Essential Eight, including physical activity, diet, sleep, and smoking cessation, as critical components of long-term risk reduction. Key Updates in 2025 Dyslipidemia Guidelines Dr. Johnson reviews the 2025 ESC/EAS-focused update, emphasizing lower LDL-C targets for high- and extreme-risk patients. She discusses the increasing use of PCSK9 inhibitors, adjunct lipid-lowering therapies, and the recommendation for routine lipoprotein(a) screening as a risk-modifying factor. Risk Assessment and Personalized Treatment Decisions For primary prevention patients, Dr. Johnson outlines how risk calculators, coronary artery calcium scoring, and comorbidities such as diabetes and metabolic syndrome guide lipid-lowering intensity. She also addresses how updated endocrine and diabetes guidelines influence earlier and more aggressive treatment strategies. Statin Intolerance and Treatment Sequencing Persistent barriers to statin use include side effect concerns, cost, and polypharmacy. Dr. Johnson shares practical strategies for managing statin intolerance, including dose adjustments, switching statins, alternate-day dosing, and the addition of non-statin therapies such as ezetimibe, bempedoic acid, and PCSK9 inhibitors. Non-Statin Therapies and New Treatment Options Dr. Johnson discusses when to escalate therapy to PCSK9 inhibitors, including monoclonal antibodies and siRNA-based agents like inclisiran. She also explains how cost, access, and insurance coverage influence real-world treatment decisions. Triglycerides and Emerging Lipid Targets While triglycerides are often overlooked, Dr. Johnson reviews their clinical significance, particularly in severe hypertriglyceridemia. She discusses lifestyle interventions, fibrates, omega-3 therapies, and emerging agents targeting ANGPTL3 and APOC-3. The Role of Lipoprotein(a) Routine Lp(a) screening is gaining momentum due to its strong association with cardiovascular disease and aortic stenosis. Dr. Johnson reviews current guideline recommendations, clinical utility, and ongoing outcome trials such as OCEAN and HORIZON that may soon reshape treatment options. Special Populations and Complex Care Dr. Johnson addresses lipid management in patients with chronic kidney disease, HIV, inflammatory diseases, and cancer, emphasizing individualized therapy and careful consideration of drug–drug interactions. Future Directions in Lipid Therapy Looking ahead, Dr. Johnson explores long-acting therapies and gene-editing approaches such as CRISPR, while highlighting the importance of health equity, access to care, and sustainable lifestyle interventions. Key Takeaway Dr. Johnson underscores that lower LDL cholesterol is better, with no identified lower limit of harm, and highlights the growing importance of lipoprotein(a) screening in cardiovascular risk assessment. As lipid therapies continue to evolve, combining guideline-driven care, patient-centered decision-making, and equitable access remains essential to improving long-term cardiovascular outcomes. Resources Website: Newsletter: Contact with Dr. Amber Johnson: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40027185

Man Enough to Feel: Breaking the Stigma Around Men’s Mental Health 03/10/2026

Man Enough to Feel: Breaking the Stigma Around Men’s Mental Health In this episode of MD Newsline, a distinguished panel of physicians, mental health leaders, former professional athletes, and performance coaches come together for a powerful discussion on men’s mental health, vulnerability, and emotional wellbeing. The conversation explores how traditional definitions of masculinity impact mental health, performance, relationships, and help-seeking behaviors—and why redefining strength is critical for future generations. Panelists include Dr. Mike Banna, Dominique Easley, Jason Sousa, Dr. Nate Evans Jr., and Dr. Pete Thomas, each bringing unique perspectives from clinical medicine, elite athletics, mental performance coaching, and community leadership. Episode Highlights Why Men Struggle to Talk About Mental Health The panel examines how stigma, fear of judgment, and societal expectations of masculinity prevent men from opening up. They discuss how emotional suppression often begins early in life and carries into adulthood, affecting relationships, leadership, and self-identity. Redefining Strength and Masculinity Vulnerability is reframed as a core component of strength—not weakness. Panelists challenge outdated narratives that equate emotional expression with failure and emphasize that resilience begins with self-awareness and honesty. Mental Health, Athletic Performance, and Life After Sports Former NFL player Dominique Easley and performance coach Jason Sousa discuss how unaddressed mental health issues can impact athletic performance and create long-term challenges after retirement. They highlight the importance of identity beyond sport and the role of emotional intelligence in sustained success. Creating Safe Spaces for Men From barbershops and coffee shops to locker rooms and clinics, the panel shares real-world examples of environments where men feel safe enough to open up. Simple check-ins, active listening, and community-based conversations are emphasized as powerful entry points. The Role of Physical Health in Emotional Wellbeing Dr. Banna explains the close connection between physical and mental health, highlighting how sleep, exercise, diet, and outdoor activity directly influence mood, stress resilience, and emotional regulation. Turning Pain Into Purpose Dr. Nate Evans Jr. shares how unprocessed pain can limit growth, while intentional healing can transform lived experience into purpose and leadership. The discussion emphasizes that resilience is built—not inherited—and healing benefits both individuals and their communities. Hope for the Next Generation The panel expresses optimism about younger generations who are more open, emotionally aware, and willing to advocate for mental health support. Early education, open dialogue, and mentorship are seen as key drivers of lasting change. Key Takeaway True strength lies in self-awareness, vulnerability, and connection. By normalizing conversations around men’s mental health and creating safe spaces for emotional expression, individuals and communities can foster healthier relationships, stronger leaders, and better outcomes across all areas of life. Resources Website: Newsletter: Contact with Panelists: · Dr. Mike Banna: · Dominique Easley: · Jason Sousa: · Dr. Nate Evans Jr: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40027150

Understanding Alzheimer’s Disease: Biomarkers and Early Detection 03/03/2026

Understanding Alzheimer’s Disease: Biomarkers and Early Detection In this episode of MD Newsline, Dr. Rudolph J. Castellani, a neuropathologist and Director of the Division of Neuropathology at Northwestern University, offers a deep dive into the biology, diagnosis, and ongoing controversies surrounding Alzheimer’s disease. He explores how Alzheimer’s is defined clinically and pathologically, the evolving role of biomarkers in early detection, and why modifying biomarkers has not yet translated into meaningful clinical improvement for patients. Dr. Castellani also discusses the promise and limitations of artificial intelligence, personalized medicine, and lifestyle interventions in Alzheimer’s research and care. Episode Highlights Defining Alzheimer’s Disease Dr. Castellani explains how Alzheimer’s disease can be defined clinically—through progressive memory and cognitive decline—or pathologically, based on hallmark brain lesions such as amyloid plaques and neurofibrillary tangles identified post-mortem. These structural changes remain central to diagnosis but do not fully explain disease progression. The Role of Amyloid and Biomarkers Amyloid beta, a key component of senile plaques, can now be detected through cerebrospinal fluid testing, blood-based biomarkers, and PET imaging. Dr. Castellani discusses how biomarkers help identify disease presence earlier but raises important questions about whether amyloid is a driver of disease or merely an associated marker. Early Detection: Promise and Ethical Concerns While biomarkers allow detection before symptoms appear, Dr. Castellani highlights the ethical dilemma of diagnosing asymptomatic individuals. He questions whether early identification without effective intervention may increase anxiety without improving outcomes. Therapies and Clinical Trial Limitations New anti-amyloid therapies, including FDA-approved agents, show only marginal cognitive benefit in highly selected trial populations. Dr. Castellani emphasizes caution when extrapolating these results to broader, more diverse patient groups and underscores the potential risks and toxicities associated with these treatments. Artificial Intelligence and Predictive Modelling AI and machine learning may enhance predictive modeling by integrating biomarkers, genetics, and cognitive data. However, Dr. Castellani notes that prediction alone is insufficient without therapies that meaningfully alter disease progression. Age of Onset and Risk Factors Alzheimer’s disease can present as early as a patient’s 30s in rare genetic cases or later in life in sporadic forms. Dr. Castellani reviews known risk factors, including APOE genotype, hypertension, diabetes, hearing loss, and traumatic brain injury, while stressing that many associations remain poorly understood. Personalized Medicine and Genetic Counseling Genetic testing—particularly for APOE and pathogenic mutations—plays a role in personalized risk assessment. Dr. Castellani emphasizes the importance of careful counseling, as not all individuals want or benefit from knowing their genetic risk. Supportive and Interdisciplinary Care With no curative treatments available, interdisciplinary care involving neurologists, neuropsychologists, and social workers is essential. Dr. Castellani highlights the importance of caregiver support, expectation management, and access to specialized centers. Lifestyle and Prevention Although lifestyle changes may not alter the underlying biology of Alzheimer’s disease, healthy diet, exercise, and reducing inflammation and oxidative stress can improve quality of life and overall health. Key Takeaway Dr. Castellani underscores that while biomarkers and amyloid-focused therapies dominate current Alzheimer’s research, they have not yet delivered meaningful clinical improvement. A broader research approach—beyond amyloid—combined with realistic expectations, ethical care, and strong support systems is essential for patients and families navigating Alzheimer’s disease. Resources MD Newsline Website: Newsletter: Contact with Dr. Rudolph J. Castellani: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40027120

From Hormones to Longevity: A Modern Approach to Men’s Health 02/24/2026

From Hormones to Longevity: A Modern Approach to Men’s Health In this episode of MD Newsline, a panel of men’s health experts—Dr. Tracy Gapin, Dr. Joseph Acquaye, and Justin Birckbichler—come together to discuss a modern, proactive approach to men’s health. The conversation explores the importance of prevention, hormone optimization, cardiovascular risk, and lifestyle-driven strategies to improve long-term health outcomes for men. The panel addresses common gaps in men’s healthcare, including delayed screenings, lack of awareness around hormone health, and the cultural barriers that prevent men from seeking early medical intervention. Drawing from clinical experience and patient education, the speakers emphasize actionable steps clinicians can take to engage male patients more effectively. Episode Highlights The Importance of Preventive Care for Men The panel discusses why men are less likely to seek preventive care and how early screening for cardiovascular disease, metabolic health, and cancer can significantly improve outcomes. Routine checkups are positioned as essential, not optional. Hormone Health and Optimization Testosterone and hormone balance play a critical role in energy, mood, body composition, and sexual health. The speakers explain when hormone testing is appropriate and how evidence-based hormone optimization can support overall wellness when done responsibly. Cardiovascular and Metabolic Risk Awareness Heart disease remains a leading cause of death among men. The discussion highlights how lifestyle factors, inflammation, insulin resistance, and obesity intersect with cardiovascular risk—and how clinicians can intervene earlier. Lifestyle Medicine and Longevity Nutrition, sleep, stress management, and physical activity are framed as foundational pillars of men’s health. The panel emphasizes sustainable lifestyle changes over quick fixes, with a focus on long-term vitality and performance. Improving Patient Engagement and Education The episode underscores the importance of communication strategies that resonate with male patients. Building trust, simplifying medical messaging, and reframing health as performance and longevity can drive better adherence. Key Takeaway Men’s health requires a proactive, preventive, and personalized approach. By addressing hormone balance, cardiovascular risk, and lifestyle factors early, healthcare providers can help men live longer, healthier, and more engaged lives. Resources Website: Newsletter: Connect with the Panelists · Dr. Tracy Gapin: · Dr. Joseph Acquaye: · Justin Birckbichler: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40006355

Connected Care in Type 1 Diabetes: Technology, Telehealth, and the Power of Patient Voices 02/17/2026

Connected Care in Type 1 Diabetes: Technology, Telehealth, and the Power of Patient Voices In this episode of MD Newsline, we explore how technology, community, and innovative care models are reshaping the experience of living with type 1 diabetes. Endocrinologist Dr. Arti Thangudu joins patient advocates Amy Hsieh (TypeOneAmy) and Jillian Rihl (T1DChic) for an in-depth conversation on digital health, telemedicine, diabetes technology, and the importance of patient-centered care. Drawing from both clinical expertise and lived experience, the panel highlights how connected devices, online communities, and new care delivery models are improving outcomes while making diabetes care more human, accessible, and empowering. Episode Highlights The Evolution of Type 1 Diabetes Technology Dr. Thangudu discusses how diabetes care has transformed over the last decade, from fingerstick monitoring to continuous glucose monitoring (CGM) systems and hybrid closed-loop insulin pumps. These advancements have reduced treatment burden, improved glycemic control, and enhanced quality of life for many patients. Living With Type 1 Diabetes: Patient Perspectives Amy and Jillian share their personal journeys with type 1 diabetes, reflecting on how technology such as Dexcom CGMs and insulin pumps has simplified daily management. Jillian describes achieving dramatic improvements in A1C through integrated devices, while Amy highlights the freedom that real-time glucose data provides in everyday life. The Power of Online Community and Social Media The conversation explores how social media platforms have created vital support networks for people with type 1 diabetes. Amy and Jillian discuss building online communities that normalize the condition, share practical insights, and reduce stigma—especially for young adults navigating life with a chronic disease. Telemedicine and Virtual Diabetes Care Dr. Thangudu explains how telemedicine can match—and in some cases outperform—in-person care for diabetes management. With improved access to CGM and pump data, virtual visits allow for more frequent, meaningful interactions and better continuity of care, particularly for patients facing geographic or logistical barriers. Direct Care Endocrinology and Patient Advocacy Dr. Thangudu introduces the direct care model, emphasizing longer visits, improved access, and hands-on advocacy for patients. This approach allows clinicians to address urgent issues, coordinate hospital care, and prevent avoidable complications such as diabetic ketoacidosis (DKA). Patient-Centered Care and Shared Decision-Making Amy and Jillian highlight the importance of recognizing that type 1 diabetes is not “one size fits all.” They advocate for individualized care plans, full transparency around technology options, and clinicians who actively listen to patients’ lived experiences. Future Innovations in Diabetes Care The panel discusses what lies ahead, including advancements in automated insulin delivery, AI-driven diabetes technology, extended-wear CGMs, and ongoing research into potential cures. While technology continues to evolve, the group emphasizes that innovation in care delivery models is just as critical. Key Takeaway This episode underscores that the future of type 1 diabetes care lies at the intersection of technology, compassion, and collaboration. By integrating digital tools, patient voices, and innovative care models, clinicians and communities can work together to create more connected, effective, and human-centered diabetes care. Resources MD Newsline Website: Newsletter: Connect with Dr. Arti Thangudu: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40006260

Life After Diagnosis: Thriving Beyond Treatment - Breast Cancer Awareness Panel 02/10/2026

Life After Diagnosis: Thriving Beyond Treatment - Breast Cancer Awareness Panel In this special panel episode of MD Newsline, recorded during Breast Cancer Awareness Month, a multidisciplinary group of experts and advocates explores the often-overlooked realities of breast cancer survivorship. Clinical psychologist and breast cancer survivor Dr. Christina Hibbert, breast and gynecologic medical oncologist Dr. Eleonora Teplinsky, and patient advocate and survivor Aisha Patterson share candid insights into the mental, emotional, social, and financial challenges that persist long after active treatment ends. Through both clinical perspectives and lived experiences, the panel highlights why survivorship is not an endpoint—but a lifelong phase requiring personalized, integrated support. Episode Highlights The Mental and Emotional Impact of Breast Cancer The panel discusses how breast cancer diagnosis and treatment are inherently traumatic experiences. Anxiety, depression, and PTSD are common among survivors, particularly after treatment concludes, when support often fades. Dr. Hibbert emphasizes that survivorship can feel more difficult than active treatment and calls for mental health care to be integrated from diagnosis onward. Life After Treatment: Survivorship Is Forever Survivors share how ringing the bell does not mark a return to “normal.” Lingering fatigue, chronic illness, fear of recurrence, and identity changes shape daily life. The panel reframes survivorship as an ongoing journey rather than a finish line. Financial Toxicity and Access to Care The discussion highlights how financial stress—from insurance gaps, treatment costs, lost income, and uncovered supportive therapies—directly impacts mental health and treatment adherence. Dr. Teplinsky explains how financial toxicity screenings and advocacy resources can help identify patients in need, while Aisha shares practical guidance on accessing grants and support programs. The Role of Community and Peer Support Social media and survivor communities play a vital role in helping patients feel seen and understood. Panelists discuss how peer networks often fill critical gaps left by traditional healthcare systems, especially for younger survivors navigating body image changes, early menopause, and long-term side effects. Caregiver and Family Support The episode underscores the emotional toll cancer takes on caregivers, partners, and children. The panel calls for better inclusion of caregivers in care planning, validation of caregiver burnout, and access to mental health resources for families affected by cancer. Redefining Thriving After Cancer Thriving looks different for every survivor. From redefining purpose and setting boundaries to honoring rest and self-care, the panel encourages patients and providers alike to embrace individualized definitions of healing and quality of life. Key Takeaway Breast cancer care must extend beyond physical treatment to address mental health, financial strain, relationships, and long-term survivorship needs. By normalizing emotional struggles, supporting caregivers, and connecting patients to meaningful resources, healthcare teams can help survivors feel less alone and more empowered throughout their journey. Resources MD Newsline Website: Newsletter: Connect with the Panelists · Aisha Patterson: · Dr. Christina Hibbert: · Dr. Eleonora Teplinsky: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/40006105

Innovation, Access, and the Future of Cardiac Care 02/03/2026

Innovation, Access, and the Future of Cardiac Care In this episode of MD Newsline, Dr. Quentin Youmans, a heart failure cardiologist at Northwestern Medicine, explores the rapidly evolving landscape of advanced heart failure care. He shares insights into guideline-directed medical therapy, emerging device-based interventions, and the growing role of personalized medicine in improving outcomes for patients with complex cardiovascular disease. Dr. Youmans also addresses health disparities, access challenges, and the importance of multidisciplinary collaboration in modern cardiology. Episode Highlights Advances in Guideline-Directed Medical Therapy (GDMT) Dr. Youmans discusses the four pillars of GDMT for heart failure with reduced ejection fraction and how rapid initiation and optimization of therapy can significantly improve patient outcomes. He emphasises early sequencing, close follow-up, and collaboration with pharmacy teams to ensure patients receive maximal benefit. Device-Based Therapies in Advanced Heart Failure Innovations such as transcatheter mitral valve repair, pulmonary artery pressure monitoring, and advanced hemodynamic devices are reshaping heart failure care. Dr. Youmans explains how these technologies help reduce hospitalizations, improve symptoms, and support earlier intervention in high-risk patients. Health Disparities and Access to Care A major focus of the conversation centers on racial, socioeconomic, and geographic disparities in heart failure outcomes. Dr. Youmans highlights efforts to expand access through community-based clinics, telehealth, and outreach to rural and underserved populations. Sex-Based Differences and Cardiovascular Risk Across the Lifespan Dr. Youmans explores how pregnancy-related conditions such as preeclampsia increase long-term cardiovascular risk for women. He underscores the need for coordinated care between cardiology, OB-GYN, and primary care to support prevention and long-term monitoring. Multidisciplinary and Collaborative Care Models Heart failure management increasingly relies on collaboration across specialties, including nephrology, endocrinology, interventional cardiology, and surgery. Dr. Youmans discusses how integrated care models improve decision-making and patient outcomes, particularly in complex cases involving CKM (cardiovascular-kidney-metabolic) syndrome. Personalized Medicine and Biomarkers Biomarkers such as BNP play a growing role in risk stratification and treatment monitoring. Dr. Youmans explains how future approaches may tailor therapies based not only on biology, but also on patients’ social environments and barriers to care. Emerging Therapies and the Future of Heart Failure Treatment From SGLT2 inhibitors and GLP-1 receptor agonists to new mineralocorticoid receptor antagonists, Dr. Youmans reviews promising pharmacologic advances for both HFrEF and HFpEF. He also shares perspectives on future innovations, including fully implantable LVADs, organ preservation technologies, and transplant expansion strategies. Key Takeaway Dr. Youmans emphasizes that the future of heart failure care lies at the intersection of innovation, equity, and collaboration. By combining advanced therapies with patient-centered communication and improved access, clinicians can meaningfully transform outcomes for diverse patient populations. Resources Website: Newsletter: Connect with Dr. Quentin Youmans: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/39757280

From Awareness to Action: Cancer Prevention & Patient Empowerment 01/27/2026

From Awareness to Action: Cancer Prevention & Patient Empowerment In this episode of MD Newsline, Dr. Aruna Anupindi, a consultant clinical oncologist based in Oxford, UK, joins the podcast to discuss evolving trends in breast and prostate cancer care. Specializing in breast and urological cancers, Dr. Anupindi shares insights from her clinical practice, highlights key takeaways from recent oncology conferences, and reflects on the growing importance of early detection, personalized therapies, and quality of life in cancer treatment. She also addresses disparities in screening uptake, emerging treatment strategies aimed at reducing chemotherapy exposure, and the role of multidisciplinary care teams in supporting patients throughout their cancer journey. Episode Highlights Shifts in Breast and Prostate Cancer Detection Dr. Anupindi discusses increased awareness and earlier diagnosis of prostate cancer, particularly among younger men, driven by public education and PSA testing. She also reflects on breast cancer screening programs and the ongoing challenge of improving participation in minority and underserved communities. Cancer Awareness and Cultural Barriers Drawing from her experience working with South Asian communities, Dr. Anupindi addresses misconceptions around cancer, cultural taboos, and the importance of education in encouraging early screening and timely diagnosis. Younger Patients and Aggressive Disease Biology Younger breast cancer patients often present with more aggressive disease. Dr. Anupindi explains why oncologists tend to take a more proactive treatment approach in this population and highlights the role of hereditary cancer risk and hormonal factors. Key Advances from ESMO and Recent Trials Dr. Anupindi shares highlights from major oncology meetings, including discussions around reducing chemotherapy exposure in HER2-positive and hormone receptor–positive breast cancer. She also explains the clinical significance of trials focused on hormone resistance and targeted combination therapies. Fertility, Pregnancy, and Cancer Treatment The conversation explores data supporting temporary interruption of endocrine therapy for young women wishing to conceive. Dr. Anupindi emphasizes that cancer survivorship should include quality-of-life considerations, including fertility preservation and family planning. Access, Affordability, and Global Equity in Cancer Care Dr. Anupindi compares treatment access across healthcare systems, discussing regulatory pathways, cost considerations, and research into lower-dose therapies that may expand access without compromising outcomes. Technology, AI, and Precision Oncology From artificial intelligence in imaging and pathology to biomarker-driven therapies, Dr. Anupindi reflects on how technology is shaping more precise, efficient, and personalized cancer care. Multidisciplinary Care and Patient Support Team-based care is central to effective oncology treatment. Dr. Anupindi highlights the essential roles of nurses, radiographers, palliative care teams, and support workers in addressing patients’ medical, psychological, and social needs. Quality of Life and Patient-Reported Outcomes As cancer treatments extend survival, Dr. Anupindi stresses the growing importance of quality-of-life measures in clinical trials and treatment decision-making, ensuring patients live better, not just longer. Key Takeaway Dr. Anupindi underscores that modern oncology is no longer focused solely on survival outcomes. Early detection, culturally sensitive education, targeted therapies, and quality-of-life considerations are essential to delivering truly patient-centered cancer care. Resources: Website: Newsletter: Connect with Dr. Aruna Anupindi: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/39757245

AI in Oncology: Building Smarter Clinical Trials and Closing Data Gaps 01/20/2026

AI in Oncology: Building Smarter Clinical Trials and Closing Data Gaps In this episode of MD Newsline, Dr. Arsela Prelaj, a thoracic oncologist and AI researcher at the Istituto Nazionale dei Tumori in Milan, Italy, explores the rapidly evolving role of artificial intelligence in oncology. Drawing from her background in medical oncology and bioengineering, Dr. Prelaj discusses how AI is revolutionizing clinical trial design, improving trial success rates, and expanding patient access to innovative therapies. She shares real-world examples of how machine learning, large language models, and synthetic data are being integrated into cancer research, while also addressing ethical considerations, data fairness, and the future of AI-driven decision-making in medicine. Episode Highlights AI in Clinical Trial Design and Drug Development Dr. Prelaj explains how AI tools are dramatically improving success rates in early-phase clinical trials. Technologies such as AlphaFold and predictive modeling are helping researchers identify promising drug targets, reduce trial failures, and optimize trial design before patients are enrolled. Predicting Trial Success and Reducing Failure AI-powered platforms can analyze historical clinical trial data to forecast the likelihood of success in Phase I, II, and III studies. Dr. Prelaj discusses how these insights benefit pharmaceutical companies, investigators, and ultimately patients by reducing exposure to ineffective treatments. Virtual Trials and Real-World Data Integration The conversation explores how virtual and pragmatic trial models leverage real-world data to simulate outcomes, relax restrictive inclusion criteria, and make trials more accessible to diverse patient populations—without compromising scientific rigor. Clinical Trial Matching and Physician Efficiency Dr. Prelaj highlights AI-driven clinical trial matching tools that can reduce physician workload by nearly 50%, helping clinicians quickly identify the most appropriate trials for individual patients while prioritizing those with the greatest potential benefit. Patient Advocacy and AI-Powered Access to Trials AI is empowering patients to actively participate in their care. Dr. Prelaj discusses patient-facing tools that allow individuals to identify relevant trials, initiate informed conversations with physicians, and advocate for access to cutting-edge treatments. Data Democratization, Bias, and Fairness The episode addresses critical challenges surrounding data governance, paywalled research, and underrepresentation in clinical trials. Dr. Prelaj explains how synthetic data and fairness auditing can help reduce disparities across race, ethnicity, and rare disease populations. The Future of AI in Oncology: Agents and Digital Twins Looking ahead, Dr. Prelaj shares her excitement about AI agents and digital twin models—dynamic systems that mirror real patients over time to support clinical decision-making, personalize treatment strategies, and enhance precision oncology. Key Takeaway Dr. Prelaj emphasizes that artificial intelligence is not replacing clinicians—but augmenting their expertise. By combining AI-driven insights with human judgment, oncology is entering a new era of smarter trials, more equitable care, and data-informed decision-making that has the potential to improve outcomes for patients worldwide. Resources Website: Newsletter: Connect with Dr. Arsela Prelaj: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/39611685

How Parity and Breastfeeding May Guard Against Triple-Negative Breast Cancer 01/13/2026

How Parity and Breastfeeding May Guard Against Triple-Negative Breast Cancer In this episode of MD Newsline, Dr. Sherene Loi, a medical oncologist and laboratory head at the Peter MacCallum Cancer Centre in Melbourne, Australia, discusses groundbreaking research published in Nature exploring how pregnancy and breastfeeding influence immune protection against triple-negative breast cancer. Dr. Loi shares insights into how reproductive history reshapes the immune system, particularly T cell activity, and how these findings may inform future prevention strategies, screening approaches, and immunotherapy development. Episode Highlights: The Immune System’s Role in Triple-Negative Breast Cancer Dr. Loi explains why the immune system is critical in triple-negative breast cancer, a subtype known to respond well to immunotherapy. Her research focuses on immune cell infiltration, particularly T cells, and how immune surveillance affects tumor growth and patient outcomes. How Pregnancy and Breastfeeding Enhance T Cell Immunity The study reveals that women who have experienced pregnancy and breastfeeding have significantly higher T cell levels in normal, cancer-unaffected breast tissue. Dr. Loi walks through both human tissue analysis and mouse model data demonstrating that this immune enrichment plays a protective role against tumor development. Evidence from Preclinical and Clinical Models Dr. Loi describes experiments showing that tumors grow more slowly in mice that have undergone pregnancy, lactation, and involution. She also explains how T cell depletion removes this protective effect, confirming that immunity—rather than hormones alone—drives this benefit. Implications for High-Risk and Diverse Populations The protective immune effect was observed regardless of BRCA1 or BRCA2 mutation status. Dr. Loi also discusses how these findings may help explain differences in triple-negative breast cancer risk across populations and highlight the importance of breastfeeding support at a public health level. Toward Preventative Immunotherapy and Vaccines This research introduces a paradigm shift—from treating cancer to preventing it. Dr. Loi explores the potential for vaccines or immune-based therapies that mimic pregnancy-related immune reprogramming and emphasizes the importance of collecting reproductive history in oncology care and clinical trials. Future Directions: Screening, Technology, and Policy Dr. Loi discusses how reproductive history may influence response to immunotherapy, inform personalized screening strategies, and shape future research using AI, T cell receptor profiling, and blood-based early detection tests. She also underscores the societal importance of supporting breastfeeding through policy and workplace initiatives. Key Takeaway Dr. Loi highlights that pregnancy and breastfeeding create long-lasting, systemic immune changes that may protect against triple-negative breast cancer. Understanding how reproductive history reshapes immune surveillance opens new avenues for prevention, personalized treatment, and population-level strategies to reduce the global burden of breast cancer. Resources: Website: Newsletter: Connect with Dr. Sherene Loi: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/39611675

Axial Spondyloarthritis: From Inflammatory Back Pain to Targeted Therapy 01/06/2026

Axial Spondyloarthritis: From Inflammatory Back Pain to Targeted Therapy In this episode of MD Newsline, Dr. Joel Wright, a rheumatology fellow at UCLA, provides an in-depth, practical discussion on axial spondyloarthritis and related spondyloarthritides. Dr. Wright breaks down evolving disease definitions, diagnostic challenges, imaging interpretation, and modern treatment strategies, while emphasizing a holistic, patient-centered approach to care. The conversation highlights how early recognition and individualized therapy can significantly improve long-term outcomes. Episode Highlights Defining Axial vs. Peripheral Spondyloarthritis Dr. Wright explains the modern classification of spondyloarthritis, distinguishing axial disease—which primarily affects the spine and sacroiliac joints—from peripheral spondyloarthritis and psoriatic arthritis. He discusses why the shift away from the term ankylosing spondylitis allows for earlier diagnosis before irreversible spinal fusion occurs. Recognizing Red Flags Across Specialties Inflammatory back pain remains the most important clinical clue, particularly pain that worsens at rest, improves with exercise, and is associated with prolonged morning stiffness. Dr. Wright also highlights extra-musculoskeletal signs—such as uveitis, psoriasis, and inflammatory bowel disease—that should prompt early referral to rheumatology. Classification Criteria vs. Clinical Judgment While ASAS classification criteria are useful for research, Dr. Wright emphasizes that real-world diagnosis relies on clinical expertise. Patients may not meet strict criteria early in the disease course, yet still warrant diagnosis and treatment based on symptoms, exam findings, labs, and imaging. MRI Use and Common Diagnostic Pitfalls MRI of the sacroiliac joints plays a central role in early detection, but Dr. Wright cautions against overreliance on imaging alone. Bone marrow edema can be seen in athletes, postpartum patients, or with aging, underscoring the importance of correlating MRI findings with clinical context. Biomarkers and Emerging Research HLA-B27, ESR, and CRP remain useful tools, though many patients have normal inflammatory markers. Dr. Wright discusses emerging biomarkers, including antibodies such as anti-CD74, and the need for more reliable tools to support earlier diagnosis. Treatment Algorithms and Medication Selection NSAIDs remain first-line therapy and may slow radiographic progression. For patients with inadequate response, Dr. Wright outlines escalation to biologics, including TNF inhibitors, IL-17 inhibitors, and JAK inhibitors—while tailoring choices based on comorbidities such as uveitis or inflammatory bowel disease. Treat-to-Target and Monitoring Early disease requires more frequent follow-up to assess response and adjust therapy. Dr. Wright explains realistic timelines for evaluating NSAIDs and biologics while balancing treat-to-target goals with clinic capacity. The Role of Exercise and Non-Pharmacologic Care Physical therapy, structured exercise, and low-impact activities such as swimming and cycling are foundational to care. Dr. Wright emphasizes the mental and physical benefits of movement, posture training, and holistic therapies alongside medication. Managing Comorbidities and Special Populations The discussion covers cardiovascular risk screening, adherence challenges in younger patients, biologic tapering in remission, pregnancy considerations, and care for older adults with established structural damage. Shared decision-making remains central across all scenarios. Key Takeaway Dr. Wright underscores that axial spondyloarthritis requires early recognition, thoughtful interpretation of imaging, and individualized treatment strategies. Combining pharmacologic therapy with exercise, multidisciplinary care, and patient education is essential to improving quality of life and preventing long-term disability. Resources Website: Newsletter: Connect with Dr. Joel Wright: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/39623405

Vitamin D, Epstein-Barr Virus, and MS Risk 01/06/2026

Vitamin D, Epstein-Barr Virus, and MS Risk In this episode of MD Newsline, Dr. Marianna Cortese, a medical doctor and epidemiologist at the Harvard T.H. Chan School of Public Health, shares groundbreaking research on the link between vitamin D, Epstein-Barr virus (EBV), and the risk of multiple sclerosis (MS). Her work, conducted within the U.S. military cohort, sheds new light on racial, genetic, and environmental factors influencing MS development and potential prevention strategies. Dr. Cortese discusses how vitamin D levels and immune response modulation play a role in MS prevention, and how EBV infection—now recognized as the leading cause of MS—interacts with genetic susceptibility and immune regulation. She also explores the future of AI in epidemiological research, the challenges of defining “deficiency” across diverse populations, and how personalized medicine may change MS prevention and treatment. Episode Highlights Understanding the Vitamin D–MS Connection Dr. Cortese explains her landmark study assessing vitamin D levels in over 1,400 MS cases and double the number of controls from a U.S. military cohort. The findings show that higher vitamin D levels are associated with a 60% lower risk of MS, even among individuals who already meet current “sufficient” vitamin D thresholds. Epstein-Barr Virus as a Causal Factor She details how EBV infection precedes nearly all MS diagnoses, increasing risk 32-fold in those infected compared to those who remain uninfected. The 2022 Science paper by her team was pivotal in confirming EBV as the primary cause of MS. Racial and Genetic Differences in Vitamin D Physiology Dr. Cortese emphasizes that Black populations may metabolize vitamin D differently, which could explain why prior studies found weaker associations between vitamin D levels and MS risk. Her ongoing work includes genotyping vitamin D transport proteins and analyzing ethnic variations in MS susceptibility. Public Health Implications and Future Research Given vitamin D’s safety, affordability, and widespread deficiency, Dr. Cortese advocates for revised supplementation guidelines tailored to disease prevention. She also highlights future research directions involving AI-driven data analysis, omics studies, and therapeutic vaccines or antivirals targeting EBV. A Look Toward MS Prevention and Treatment Dr. Cortese envisions a future where antiviral therapies against EBV could transform MS management—potentially leading to disease-modifying or curative interventions. Meanwhile, maintaining sufficient vitamin D remains a key, accessible step for reducing risk. Key Takeaway Dr. Cortese’s research bridges decades of inquiry into how vitamin D and EBV intersect to influence MS risk. Her findings reinforce the importance of immune health, genetic understanding, and early prevention, paving the way for more personalized and equitable approaches to neurological care. Resources Website: Newsletter: Connect with Dr. Marianna Cortese: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/38903890

Living With HS: Tameka Carter’s Journey to Diagnosis and Treatment 01/02/2026

Living With HS: Tameka Carter’s Journey to Diagnosis and Treatment In this episode of MD Newsline, patient advocate Tameka Carter shares her personal journey living with hidradenitis suppurativa (HS), a chronic, painful inflammatory skin condition often misdiagnosed for years. Tameka discusses the early signs of HS, the emotional and physical toll of delayed diagnosis, and the importance of finding a specialist who truly listens. She offers valuable insight into treatment decision-making, lifestyle changes, and the critical role of self-advocacy in managing a lifelong condition. Episode Highlights Early Symptoms and Delayed Diagnosis Tameka reflects on experiencing painful boils as early as adolescence, often dismissed as razor bumps, cysts, or irritation. Despite recurring symptoms, she did not receive an HS diagnosis until 2019—highlighting a common challenge many HS patients face. Impact of Hormones and Life Changes Symptoms became more frequent and severe in her early 20s, particularly after pregnancy. Over time, Tameka began noticing patterns related to her menstrual cycle, helping her better understand flare triggers. The Emotional and Physical Burden of HS Living with chronic pain, drainage, and scarring significantly affected Tameka’s quality of life and confidence. She shares how unmanaged HS can quietly take over daily living when symptoms become constant. Finding the Right Specialist Tameka emphasizes the turning point in her care after seeking a dermatologist who specializes in HS. Under the care of Dr. Onajin, she experienced a more aggressive, responsive treatment approach that prioritized real pain reduction and patient feedback. Personalized Treatment and Pain Measurement Rather than a one-size-fits-all approach, treatment success was measured by meaningful pain reduction percentages. This patient-centered strategy allowed Tameka and her care team to adjust therapies quickly when something wasn’t working. Procedures, Medications, and Combination Care Tameka discusses the role of biologics, steroid injections, surgical procedures, and scar tissue removal as part of a comprehensive treatment plan—emphasizing that improvement was gradual, not overnight. Nutrition and Lifestyle as Key Triggers Diet emerged as one of the most impactful factors in managing HS. Tameka shares how eliminating refined sugar, dairy, and soda helped reduce flares, improve energy levels, and support overall well-being. Advocacy, Education, and Listening to Your Body A strong advocate for patient education, Tameka encourages others to research their condition, speak up when treatments fail, and seek second or third opinions. She underscores that patients know their bodies best—and deserve to be heard. Advice for Patients and Providers Tameka offers powerful guidance for those living with HS and for healthcare providers: listen, communicate clearly, and treat patients as partners in care. Key Takeaway Tameka Carter’s story highlights the importance of early recognition, specialist care, and patient advocacy in managing hidradenitis suppurativa. Meaningful progress happens when patients are heard, treatments are personalized, and care teams act with urgency and compassion. Resources Website: Newsletter: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/39589855

How Ultra-Processed Food Impacts MS Progression 12/30/2025

How Ultra-Processed Food Impacts MS Progression In this episode of MD Newsline, Dr. Gloria Dalla Costa, a researcher at Harvard University, shares groundbreaking insights into the role of ultra-processed foods in multiple sclerosis (MS) progression. Drawing from her research on environmental and metabolic risk factors, Dr. Dalla Costa discusses how dietary habits may influence inflammation, disease activity, and long-term neurological outcomes in MS patients. Her work reveals compelling evidence that higher consumption of ultra-processed foods correlates with increased inflammatory markers, worsened MRI outcomes, and a greater risk of relapse. By analyzing blood-based metabolic signatures, her team is uncovering how these foods interact with biological pathways tied to chronic inflammation and neurodegeneration. Dr. Dalla Costa also discusses the Nova classification of processed foods, the role of ceramides and other metabolites in cellular health, and how regional dietary patterns affect disease outcomes. She emphasizes the importance of adopting a Mediterranean-style diet and reducing ultra-processed food intake as a modifiable lifestyle factor that can complement established MS therapies. Episode Highlights Exploring Environmental Risk Factors for MS Dr. Dalla Costa explains how her team investigates multiple environmental contributors to MS, including Epstein–Barr virus exposure, vitamin D levels, and now, ultra-processed food intake. Ultra-Processed Foods and Disease Activity Her findings show that MS patients with higher levels of ultra-processed food metabolites in their blood experience 30% more relapses and worse MRI lesion progression over five years. Metabolic Signatures and Biomarkers Dr. Dalla Costa outlines how measuring circulating metabolites in blood and urine offers an innovative way to assess dietary exposure objectively, bypassing unreliable food questionnaires. Dietary Classification and Health Impact The Nova system distinguishes between unprocessed, minimally processed, processed, and ultra-processed foods. Additives, preservatives, and colorants—while convenient—are linked to inflammation and metabolic stress. Towards Personalized Nutrition in MS Emerging evidence suggests that dietary modification could become a complementary approach in MS management. Dr. Dalla Costa envisions a future where AI and machine learning will personalize nutritional recommendations for patients. Future Directions in Research Her team plans to explore how ultra-processed foods affect the gut barrier, contribute to chronic inflammation, and potentially inform dietary policy and patient education globally. Key Takeaway Dr. Dalla Costa underscores that reducing ultra-processed food intake may serve as a simple yet powerful tool to support neurological health in MS patients. By combining validated therapies with mindful dietary choices, clinicians and patients can work together to mitigate inflammation and improve long-term outcomes. Resources Website: Newsletter: Connect with Dr. Gloria Dalla Costa: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/38855720

Biomarkers in Multiple Sclerosis: Tracking Disease Progression 12/23/2025

Biomarkers in Multiple Sclerosis: Tracking Disease Progression In this episode of MD Newsline, Dr. Ahmed Abdelhak, Assistant Professor of Neurology at the University of California, San Francisco, explores the cutting-edge world of fluid biomarkers in multiple sclerosis (MS). With over a decade of experience as an MS clinical scientist, Dr. Abdelhak shares his expertise on the evolving role of biomarkers in understanding, predicting, and managing MS progression. He breaks down how markers like neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and chitinase (CHIT1/CHIT3) offer insights into the underlying neuroinflammatory and neurodegenerative processes in MS. From identifying axonal damage to detecting astrocyte activation and microglial involvement, these biomarkers are transforming how clinicians assess disease activity and progression risk. Dr. Abdelhak also discusses the potential of machine learning and AI-based models in interpreting complex, multi-center datasets — paving the way for personalized treatment strategies. He emphasizes the importance of cross-specialty collaboration, incorporating radiology, immunology, and physical therapy, to deliver holistic MS care that addresses both neurological and everyday challenges faced by patients. Episode Highlights Advancements in MS Biomarkers Dr. Abdelhak reviews emerging biomarkers — including GFAP and chitinases — and explains their cellular origins, from astrocytes to microglia, offering a multidimensional view of disease mechanisms. Clinical Value of GFAP and NFL He explains how GFAP reflects astrocyte activation and correlates with disease progression, while NFL indicates axonal damage. Combining both markers enables a more precise prediction of MS activity and long-term disability outcomes. Machine Learning and Data Integration AI is reshaping MS research by harmonizing large, noisy datasets and uncovering biologically meaningful clusters of patients. This integration of fluid, imaging, and genetic data supports early identification of disease subtypes and better treatment matching. Personalized and Holistic MS Management Dr. Abdelhak underscores the future of individualized biomarker trajectories, which could guide treatment adjustments and predict therapy response. He also highlights the need for patient advocacy, encouraging individuals to voice concerns about cognitive symptoms, fatigue, and depression often overlooked in clinical settings. The Path Ahead for MS Research He anticipates major breakthroughs in the next five years, especially in identifying new biomarker panels and understanding under-researched pathways involving astrocytes and microglia. Collaboration across specialties and clearer communication with patients will be crucial to translating these scientific insights into daily clinical care. Key Takeaway Dr. Ahmed Abdelhak emphasizes that fluid biomarkers are redefining MS care — enabling earlier, more accurate detection of disease progression and treatment response. The integration of AI tools, multi-omics data, and cross-specialty collaboration is driving a new era of precision medicine in neurology, offering patients more informed and individualized care pathways. Resources Website: Newsletter: Connect with Dr. Ahmed Abdelhak: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/38855650

Optic Neuritis, MS Differentials, and Modern Treatment Pathways 12/16/2025

Optic Neuritis, MS Differentials, and Modern Treatment Pathways In this episode of MD Newsline, Dr. Nilüfer Kale, Head of the Department of Neurology at Başakşehir Çam and Sakura City Hospital in Istanbul, Turkey, provides an in-depth look into optic neuritis, multiple sclerosis (MS), and related demyelinating disorders. She discusses the pathophysiology, diagnostic challenges, and treatment evolution of these conditions—offering valuable insights for clinicians managing autoimmune neuroinflammatory diseases. Dr. Kale also highlights the importance of accurate differential diagnosis, the role of neuroimaging and biomarkers, and how advancements in remyelination research are shaping the future of MS treatment. Episode Highlights Epidemiology and Patient Demographics Dr. Kale explains that autoimmune neurological disorders such as MS and optic neuritis predominantly affect young women in their childbearing years. She attributes this trend to the interplay of hormonal, genetic, and environmental factors, including vitamin D deficiency, Epstein–Barr virus exposure, and obesity. Pathophysiology of MS and Optic Neuritis She provides a detailed overview of how immune system activation, particularly involving T cells, B cells, and cytokines, leads to demyelination and subsequent neurodegeneration. While early disease stages may allow remyelination, progressive degeneration contributes to long-term disability. Diagnosis and Differential Considerations Dr. Kale emphasizes that early and accurate diagnosis is critical to preventing irreversible damage. Conditions such as neuromyelitis optica (NMO) and MOG antibody disease (MOGAD) can mimic MS, underscoring the need for MRI imaging, CSF analysis, and antibody testing to guide correct classification and treatment. Clinical Presentation and Early Detection Optic neuritis often presents with eye pain, color desaturation, and central vision loss. Dr. Kale notes that orbital and cranial MRI scans with contrast are essential for confirming inflammation and ruling out other causes such as ischemic optic neuropathy or ophthalmologic conditions. Treatment Strategies and Advances Standard management involves high-dose intravenous corticosteroids to accelerate visual recovery and delay MS onset, as shown in the Optic Neuritis Treatment Trial (ONTT). For severe or atypical cases, Dr. Kale recommends plasmapheresis or IV immunoglobulin (IVIG) therapy. She stresses tailoring therapy to the individual patient, noting that treatment protocols for MS, NMO, and MOGAD differ significantly. Evolving Therapies and Global Access Dr. Kale reflects on the progress from early interferon-based therapies to modern monoclonal antibody treatments, highlighting how health policy and access continue to affect patient outcomes worldwide. Emerging Research and Biomarkers Advances in PET imaging and astrocyte-targeted ligands show promise for identifying chronic lesions and smoldering plaques, which could pave the way for future remyelination-focused treatments. Patient-Centered Care and Gender Considerations Beyond science, Dr. Kale underscores the emotional and social burden faced by women living with MS—balancing family responsibilities, work, and health. She advocates for stronger patient networks and social support systems to improve quality of life. Key Takeaway Dr. Kale emphasizes that timely diagnosis, personalized therapy, and advances in neuroimaging and immunology are transforming MS and optic neuritis care. She calls for continued collaboration between clinicians, researchers, and policymakers to ensure equitable access to modern treatments and better long-term outcomes for patients. Resources Website: Newsletter: Connect with Dr. Nilüfer Kale: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/38855590

Sybil AI and Precision Lung Cancer Screening 12/08/2025

Sybil AI and Precision Lung Cancer Screening In this episode of MD Newsline, Dr. Frank Weinberg, a thoracic oncologist at the University of Illinois Cancer Center, explores the groundbreaking integration of artificial intelligence (AI) into lung cancer screening. As the senior author and a key collaborator in the SIBL (Sybil) Consortium, Dr. Weinberg shares how this AI tool—originally developed by MIT’s Regina Barzilay and validated at Mass General Hospital—is being expanded to assess its effectiveness in diverse and underserved populations. He discusses how SIBL uses low-dose CT scans to predict a patient’s six-year risk of developing lung cancer, addressing a critical gap in current screening guidelines that often overlook individuals who don’t meet standard age or smoking history criteria. Through collaboration with colleagues like Mary Pasquinelli, Dr. Weinberg highlights how the University of Illinois is advancing precision-based lung cancer screening that reflects real-world diversity. Episode Highlights AI for Early Lung Cancer Detection Dr. Weinberg explains how the SIBL tool analyzes CT scans to detect subtle patterns invisible to the human eye—allowing clinicians to predict lung cancer risk before tumors are visible. Unlike traditional screening models based solely on age and smoking history, SIBL offers a personalized, data-driven approach. Expanding Validation Across Diverse Populations The SIBL Consortium, which includes UIC, Baptist Memorial (Tennessee), and WellStar (Southeast U.S.), is working to validate the AI tool in heterogeneous populations. The goal is to ensure that racial and socioeconomic diversity is represented in lung cancer screening research. Integrating Biology with AI Insights Dr. Weinberg discusses his lab’s efforts to combine biological data—such as cytokine levels, metabolites, and genetic profiles—with SIBL scores. This approach aims to deepen understanding of oxidative stress, inflammation, and genomic markers that influence lung cancer risk. From Screening to Prevention Moving beyond detection, Dr. Weinberg envisions a future of precision-guided lung cancer prevention, where AI-driven insights and biomarker data could identify high-risk patients and enable early interventions to reduce cancer incidence altogether. Bridging Health Disparities Because current screening criteria disproportionately exclude Black and underserved patients, validating SIBL in diverse cohorts can help correct systemic inequities. Dr. Weinberg emphasizes that technology like SIBL, when responsibly deployed, can reduce disparities and improve early detection outcomes. Challenges and Next Steps Dr. Weinberg also reflects on the technical, ethical, and logistical challenges of implementing AI tools in healthcare systems. From data privacy and interoperability to community trust and educational outreach, he stresses that responsible innovation requires collaboration between clinicians, data scientists, and patients alike. Key Takeaway Dr. Frank Weinberg underscores the transformative potential of AI-powered precision medicine to revolutionize lung cancer screening and reduce disparities in healthcare. By validating tools like SIBL across diverse populations and integrating biological, clinical, and social data, the medical community can move closer to achieving truly equitable early detection and prevention. Resources Website: Newsletter: Connect with Dr. Frank Weinberg: /episode/index/show/ecb5ed55-2779-489f-bef7-9484228289f1/id/38791630

Beyond the Delivery Room: Data, Doulas, and Patient-Centered OB-GYN 12/02/2025

Infant Feeding, Early Habits & Childhood Obesity: What Parents Need to Know 11/25/2025

The Future of Myeloma: Quadruplets, CAR-T & Beyond 11/18/2025

HPV Throat Cancer Misdiagnoses And How Technology Shapes ENT Health 11/11/2025

Personalized Approaches to Metabolic Liver Disease and MASH Management 11/04/2025

What's Next in Diabetes Care: New Treatments and Tech Insights 10/28/2025

MD Newsline

TOPICS